Home / Market News / $AUTL
fiscal.ai Corporate Catalyst Impact 85/100 ● positive

Autolus Therapeutics Reports Third Quarter 2026 Financial Results

Nov 10, 2026, 5:32 PM UTC · Primary ticker $AUTL

Autolus Therapeutics reported strong Q3 2026 financial results, significantly increasing net product revenue for its lead therapy, AUCATZYL, year-over-year. This performance led the company to raise its full-year 2026 revenue guidance, now expecting to meet or exceed the upper end of its previous forecast, and extended its cash runway into Q2 2028.

Autolus Therapeutics announced robust Q3 2026 results, with AUCATZYL net product revenue nearly doubling year-over-year. This strong performance is a significant positive catalyst, leading the company to raise its full-year 2026 revenue guidance for AUCATZYL, indicating better-than-expected market adoption and sales. The extended cash runway into Q2 2028 also alleviates near-term funding concerns, providing financial stability. This news is highly positive for Autolus (AUTL) in the short term, potentially driving its stock price higher due to improved financial outlook and reduced operational risk. Long-term implications depend on continued AUCATZYL growth and pipeline development, but the immediate impact is a strong vote of confidence in its commercial strategy.

$AUTL positive Strong revenue growth and raised guidance
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.